Good morning, welcome to Acadia Healthcare's Fourth Quarter and Full- Year 2022 Earnings Call. All participants will be in a listen-only mode. Should you need any assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there'll be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star then two. Please note that this event is being recorded today. I would now like to turn the conference over to Gretchen Hommrich. Please go ahead, ma'am. Good morning, welcome to Acadia's fourth quarter 2022 conference call. I'm Gretchen Hommrich, Vice President of Investor Relations for Acadia. I'll first provide you with our safe harbor before turning the call over to our Chief Executive Officer, Chris Hunter. To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link. This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2022 and beyond. You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's fourth quarter news release. Consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. At this time, for opening remarks, I would like to turn the conference call over to our Chief Executive Officer, Chris Hunter. Thank you, Gretchen. Good morning, everyone, and thank you for being with us today for our fourth quarter 2022 conference call. I'm here today with Chief Financial Officer, David Duckworth, and other members of our executive management team. David and I will provide some remarks about our financial and operating performance for the fourth quarter of 2022 and guidance for 2023. Following our comments, we'll open the line for your questions. In December, we held our first ever Investor Day at Carnegie Hall in New York. We're appreciative that so many of you joined us in person and through our webcast. It was a great event. We appreciate your support. I'm pleased to say that our fourth quarter results and start to 2023 demonstrate that we're executing on the strategy we presented with favorable results across our key performance metrics. Throughout the past year, we continued to see strong momentum in our business, reflecting robust demand for our behavioral healthcare services. We need to continue to commend our dedicated team of employees and clinicians across our operations who've worked tirelessly to meet the needs of those seeking treatment for mental health and substance use issues. Our strong results reflect our ability to effectively operate our 250 facilities across Acadia's network and serve our patients with safe, quality care. During the fourth quarter, we continued to see positive trends in our business with an increase in our same-facility revenue of 9.4% compared with the fourth quarter of 2021, including an increase in revenue per patient day of 5.2% and an increase in patient days of 4.0%. Our fourth quarter results marked a strong finish to 2022 and we believe set us up well for 2023. We are proud of our vitally important work to support expanding patient populations in order to make a positive difference in more communities. Acadia has created a strong foundation to build upon during a time of unprecedented demand for behavioral healthcare services. A recent 2022 study from Indiana University found that approximately 45% of patients who visit the emergency department for physical injuries and ailments also have mental health and substance use problems that are frequently overlooked. Acadia has established strong relationships with med-surg hospitals across the country, bringing our experience and expertise to markets where they are desperately needed. Fortunately, a greater social awareness of mental health issues and broader acceptance of treatment have made behavioral healthcare a priority with medical professionals and government healthcare officials. Acadia is well positioned to address this critical societal need as a leader in providing behavioral healthcare services across the care continuum. During the fourth quarter of 2022, we continued to advance our growth objectives across each of our service lines. As we've previously shared, we believe our five distinct growth pathways will enable the company to meet this demand and extend our market reach. I'll briefly update you on our accomplishments related to these five pathways during the fourth quarter. On the first pathway, facility expansions remains a primary driver of our growth, as this pathway allows us to efficiently expand services in established markets by utilizing our existing infrastructure and experienced staff. We added 80 beds to our existing facilities during the fourth quarter, finishing the year with a strong second half performance with 212 bed additions and bringing our total number of bed additions to 290 for the year. Looking ahead, we expect to add approximately 300 beds through facility expansions in 2023. Importantly, many of the bed additions in 2023 will open in the first half of the year and are expected to contribute to an accelerating volume growth outlook for the company. A second important growth pathway is to identify underserved markets for behavioral healthcare services and develop wholly owned De Novo facilities that bridge this gap and help meet the critical community need. In 2022, we opened a 60-bed children's hospital as the first stage of our Montrose Behavioral Health Hospital operations in Chicago. We look forward to increasing the pace of our De Novos from opening one per year to two per year in 2023, as we're on track to open our 101-bed Montrose Adult Hospital and outpatient facility in our 80-bed facility, Coachella Valley Behavioral Health in Indio, California, later this year. We're excited to announce a new De Novo facility that is slated to open in 2024. This 100-bed acute care behavioral health hospital will serve the residents of Mesa, Arizona, and surrounding communities. Agave Ridge Behavioral Hospital will offer a full continuum of inpatient behavioral healthcare services for adult, older adult, adolescent, and child patients. Our groundbreaking is scheduled for next week. We will continue to pursue additional De Novo opportunities in other underserved markets with a goal to develop and open acute and specialty facilities in 2024 and beyond. We also continued to expand our network of comprehensive treatment center facilities, or CTCs, specifically designed to meet the growing and critical need for addiction treatment, especially for patients dealing with Opioid Use Disorder. During the fourth quarter, we opened three new De Novo CTCs in Florida and Delaware, bringing our total to seven new CTCs for the year, which exceeded our goal of at least 6 CTCs. As the opioid crisis has continued to escalate across the country, we believe Acadia CTC facilities play a vital role in the communities they serve, with programs that combine behavioral therapy and medication to treat Opioid Use Disorders. Each CTC provides a range of comprehensive substance use treatment support services that include medical, counseling, vocational, educational, and other treatment services to help our patients progress. We will continue to expand our CTC network and service offerings to meet this essential need with an objective of adding 6 CTCs in the year ahead. Our third attractive growth pathway is forming strategic partnerships with leading health systems across the country. We've been fortunate to establish strong relationships with leading national healthcare providers and premier healthcare systems who want to expand behavioral healthcare treatment options in their respective communities. We bring the clinical expertise and experience they need to deliver high-quality care, while we have an opportunity to leverage the provider's market presence and establish relationships in the community. In the second half of 2022, we were pleased to open two new facilities. The first facility was a 90-bed facility with our joint venture partner, Covenant Health, in Knoxville, Tennessee, in August. The second facility was Maple Heights Behavioral Health, a 120-bed facility, which was opened in December with our partner, Lutheran Health Network, in Fort Wayne, Indiana. Acadia now has 19 joint venture facilities in various stages of development, with nine facilities opened and 10 facilities expected to open over the next several years, including two in 2023. We remain encouraged by the strong continued interest from potential partners in our JV pipeline. For our fourth growth pathway, we have maintained a very disciplined focus on M&A opportunities and continue to look for selective acquisitions that complement our growth strategy and are incremental to our financial objectives. During the fourth quarter, we acquired 4 CTCs from Brand New Start Treatment Centers located in separate suburbs of the Atlanta metropolitan area, extending Acadia's CTC network to 151 locations at the end of 2022. We remain focused on selectively identifying attractive M&A opportunities that are complementary to our existing geographic footprint and portfolio of service offerings. We are fortunate to have a strong balance sheet that provides the flexibility to pursue acquisitions as well as make the necessary investments to support our other strategic growth pathways. For our fifth and final growth pathway, we remain focused on extending the continuum of care across our facilities and identifying additional ways to support patients. For example, we are continuing to strengthen our mid-level acuity programming, which we most often use to step down our patients after residential treatment. Since 2019, we have added over 50 PHP and IOP programs, including five in Q4 2022 alone. We are also continuing to advance our cross-referral program, including by launching system improvements in Q4, which make it easier for our nurses and clinicians to identify cross-referral opportunities and facilitate the referral process itself. Finally, we continue to fill in service line gaps in our markets. Our previously mentioned acquisition of 4 CTCs in the Atlanta area, for example, complements our existing Acute Specialty PHP and IOP service lines in that market. In conclusion, we are well-positioned to maintain our strong growth trajectory and meet our development targets for the year, which are adding approximately 670 beds in 2023 through approximately 300 bed additions to existing facilities, opening two inpatient De Novo facilities, two facilities with JV partners with more JV announcements to come, and opening at least 6 CTC locations. We're working hard to deliver on our 2024 and 2025 growth targets, as well as strengthening the foundation that these new facilities will become a part of. As Acadia continues to lead and grow, we are committed to creating and implementing best-in-class IT solutions that will further enhance the delivery of care and support the patients we serve. As we discussed in our Investor Day, investments in technology will be a key area of focus for Acadia in 2023 and beyond. We are accelerating investments where we can strengthen our capabilities and lead the industry forward by leveraging technology to increase access to care, improve the delivery of care, and ultimately support clinical integration and operational efficiencies. Initially, the areas where we expect to make short-term investments include enhancing our infrastructure, which involves improving all of Acadia's technology capabilities across our network. A top priority is centered around electronic medical records. Today, we have manual paper-based processes across most of the company, and the potential for electronic medical records is a significant opportunity for not only Acadia, but also the industry. As we migrate to electronic records, there are significant benefits from both a clinical and financial perspective. We are focused on technology investments across five main categories. The first is that we'll be able to better support our medical teams with respect to patient safety and compliance. Second, we believe these investments will enhance the overall patient experience. Third, we expect improvement in employee satisfaction, which will support recruiting and retention. Fourth, the additional data and analytics capabilities will also help us engage with payers as we are better able to support value-based care and identify operational efficiencies. Finally, we believe these disciplined investments will drive revenue and margin improvement opportunities for the company over time. As we communicated in December at our Investor Day, we expect to allocate approximately $35 million-$45 million in IT investments in the coming year, of which $15 million-$25 million is incremental to our historical investment. We will continue to evaluate the value derived from these investments and believe that over the four-year period from 2023 to 2026, that we could see a total of $75 million-$125 million in dedicated IT incremental capital expenditures. We are highly encouraged by the value that this will provide for Acadia as we lead the industry forward in leveraging technology to improve the delivery of care. We also noted in December, we had planned to add key leadership for this important initiative, and we're pleased to add that Laura Groshon joined Acadia as the company's new Chief Information Officer in early January. Laura joins Acadia with over 25 years of experience driving strategic transformation at large healthcare and consumer-focused IT organizations. She most recently served as the business unit CIO of Medtronic, the $30 billion global healthcare solutions company, where she led a team supporting information and technology for 20 operating units and global business functions across Medtronic's locations in 150 countries. As Acadia CIO, Laura will shape and advance our IT strategy as an integral part of our digital transformation. She will drive continued digital transformation across Acadia's scaled behavioral health capabilities. I also wanna reinforce our commitment to quality across our operations. As we continue to extend our market reach, safe and quality care remains the top priority for the patients who seek our help. I'm pleased to announce that we recently added Dr. Navdeep Kang to our management team as our new Chief Quality Officer for inpatient services. In this role, Nav will work closely with our Chief Medical Officer, Dr. Mike Genovese will be responsible for ensuring patient safety and superior quality of care by improving delivery of clinical services in our inpatient facilities. Nav will lead our initiative to provide a robust, proactive culture of quality and excellence, supported by processes and systems designed to prevent any issue and, when necessary, quickly respond to any adverse events. Nav is a clinical psychologist and brings extensive experience in addiction treatment and behavioral health. As we look to the year ahead, we remain focused on increasing our pace of growth and capitalizing on expansion across our service lines. At the same time, we'll look for ways to improve upon the delivery of care we provide and strengthen our capabilities with the right technology investments and differentiated services that drive improved clinical outcomes. Across our network of 250 facilities, we have a shared mission to provide high-quality behavioral health care services, and we look forward to the opportunities ahead for Acadia in 2023 and beyond. At this time, I will now turn the call over to David Duckworth to discuss our financial results for the quarter and 2023 guidance. Thanks, Chris. Good morning. Looking at the fourth quarter, we delivered strong financial and operating results as we successfully delivered on our key performance metrics, demonstrating consistent execution of our strategy. Revenue for the fourth quarter of 2022 increased 13.8% to $675.3 million compared with $593.5 million for the fourth quarter of 2021. Our revenue growth includes an increase in same-facility revenue of 9.4%. For the fourth quarter, our adjusted EBITDA was $150.9 million, and adjusted income attributable to Acadia stockholders per diluted share was $0.74, which includes income of $5.2 million related to the Provider Relief Fund, also related to the American Rescue Plan payments. Adjustments to income for the fourth quarter of 2022 include transaction-related expenses and the related income tax effect. The company also recorded an unfavorable adjustment of $5.9 million or $0.05 per diluted share to its self-insured professional and general liability reserves relating to the settlement or expected settlement of certain prior year claims relating primarily to the 2017-2018 period. The estimated accrual for professional and general liabilities is based on historical claims, prior settlements and judgments, and other factors and actuarial assumptions. While we could see volatility in this reserve due to our self-insured retention level of $5 million, we view this fourth quarter adjustment as a nonrecurring item relating to unique facts and circumstances for certain claims in that 2017-2018 period. From a cost management perspective, we were pleased with our execution throughout 2022. While we saw higher wage inflation in 2022, including approximately 8% base wage inflation for the fourth quarter, we believe it's important to remain proactive in our pay, and our volume and reimbursement growth have remained strong. While base wage inflation is expected to remain higher in the 7%-8% range in the first half of 2023, we are seeing positive recent hiring trends, and we also saw an 8% sequential reduction in premium pay from the third quarter to the fourth quarter of 2022. Maintaining a strong financial position will remain a top priority for 2023, providing us the flexibility and capital to support our growth strategy and future investments. As of December 31st, 2022, the company had $97.6 million in cash and cash equivalents and $525 million available under its $600 million revolving credit facility with a net leverage ratio of approximately 2.1 times. During the Q4, the company completed its repayment of amounts received pursuant to the Medicare Accelerated and Advanced Payment program under the CARES Act. Of the $45.2 million of advanced payments received in 2020, the company repaid a total of $25.1 million in 2021 and paid the remaining $20.1 million in 2022, including $1.2 million in the Q4 2022. Moving on to our guidance. As noted in our press release, we narrowed our previously issued guidance for 2023 as follows: Revenue in a range of $2.82 billion-$2.88 billion. Adjusted EBITDA in a range of $635 million-$675 million. Adjusted earnings per diluted share in a range of $3.10-$3.40. Interest expense in a range of $80 million-$85 million. A tax rate in the range of 25%-26%. Depreciation and amortization expense in a range of $125 million-$135 million. Stock compensation expense in a range of $30 million-$35 million. Operating cash flow in a range of $450 million-$500 million. Expansion capital expenditures in a range of $350 million-$400 million. Maintenance capital expenditures in a range of $40 million-$50 million. IT capital expenditures in a range of $35 million-$45 million. We also established financial guidance for the first quarter of 2023, including revenue in a range of $690 million-$700 million, adjusted EBITDA in a range of $145 million-$150 million, and adjusted earnings per diluted share in a range of $0.70-$0.74. The company's guidance does not include the impact of any future acquisitions, divestitures, transaction-related expenses, or the recognition of any additional Provider Relief Fund income. With that, Joe, we are ready to open the call for questions. We will now begin the question-and-answer session. To ask a question, you may press star, then one on your touch-tone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. We ask that you please limit yourself to one question and one follow-up. At this time, we will pause just momentarily to assemble our roster. Our first question will come from A.J. Rice with Credit Suisse. Please go ahead. Thanks. Hi, everyone. I know at the Investor Day and in your comments today, you've talked a little bit about the potential acquisition pipeline that's out there for you. I wondered if you'd expand a little more on what you're seeing. You know, it seemed like there's a lot of JV and potential acquisition opportunities coming out of the pandemic. Is that still there? Is there any opportunity that you think this year as you look out for larger deals, are there any of those potentially out there? Yeah, thanks. Thanks, A.J. This is Chris. I'll start. We continue to feel very optimistic about the M&A pipeline, which is, you know, clearly one of our important growth levers for 2023. You know, I would say that we have done extensive work in looking at the under-bedded markets and really targeting the MSAs where we believe we have the most upside potential over time. We're always looking to find ways to optimally deploy capital, whether that is doing more JVs, doing De Novos, clearly looking at M&A. You know, right now we feel very good about the pipeline that we have on the M&A front. I feel also, you know, that we have some confidence that valuations are, you know, slightly softening as we're heading here into the new year. I would say to your question on the JV front, we also feel very strong about the pipeline there. You know, our existing JV announcements are expected to take us from our current acute states of 21 plus Puerto Rico into three additional states, Colorado, Minnesota, and North Carolina. The pipeline of near-term deals on the JV front are expected to take us into two additional states, and I think really just strengthen our geographic footprint overall. We feel very good about the pipeline that's building in these MSAs, on the JV front, certainly with De Novos and definitely with M&A as well. Okay, great. Maybe my follow-up, obviously the 9.4% revenue increase is a robust number. I wonder if you could give us a little flavor for across the individual segments, was that a consistent rate of growth, or was there much variation across your key business lines? Yeah, A.J., we were pleased with the same-facility revenue performance in the quarter, which included another strong quarter of revenue per day growth and our strongest quarter of the year from a volume perspective. As we look at that by service line, we saw incredibly strong performance, demand, volume, pricing, really across all of the service lines. We would highlight acute, specialty, and the CTC business all saw a very strong quarter. RTC also performed well, very stable. Of course, there are fewer investments going into that service line, but the facilities we have had a very good 2022 and fourth quarter. Acute, specialty, and CTC really led the charge in terms of revenue growth for the quarter. Okay, great. great. Thanks. I would just add, you know, for 2023, we really continue to expect strong patient day growth of 4%-6% for the year. I would say that the volume is supported by three things. You know, the first is just our strong demand that continues. The second would be the important capacity additions that we've seen and that we just discussed in the second half of 2022 that will continue to early 2023. The third is just the improved performance that we're starting to see from optimizing our marketing and admissions processes. It's early in the year, but so far into the quarter, we're seeing record census and patient day growth that we really think is at the higher end of the 4%-6% that we're projecting for the year. Okay, great. Thanks so much. Yeah. Our next question will come from Whit Mayo with SVB Securities. Please go ahead. Hey. Thanks. Maybe for David or actually more for Chris. When you guys look at the capital that you're deploying, have you changed at all or refined how you measure returns on capital? I'm just wondering how the returns have changed on these deals and what your minimum hurdle rates are today. It might just be more helpful to frame from, like, a cohort perspective how capital returns are tracking. Whit Mayo, we always refine how we think about allocating capital across our growth pathways, across our service lines, and haven't necessarily changed how we think about our targets. Certainly, like a lot of companies would say, our weighted average cost of capital and the cost of debt has increased slightly. You know, from our perspective, we've always built in kind of a higher threshold that we target in our transactions, such that we haven't had to significantly change how we think about that capital allocation. We continue to think that our existing facility expansions are our most attractive opportunity. And then as we think about De Novos and as we think about joint ventures and even M&A opportunities, we have a, you know, a deal-specific analysis that we look at. Across those growth pathways, we're still seeing, you know, good opportunities that exceed the hurdles that we have in place across a number of different metrics, IRR. We look at ROIC, we look at our EBITDA multiple, not only at the time that we make an investment, but over the course of the investment as we hope to grow earnings, whether, you know, that's an M&A deal or, you know, a De Novo or a joint venture facility. No, no major changes. Of course, as we projected out in December, there are many joint venture projects that we think will be tremendous for the company that we're working hard to bring online and bring good EBITDA growth for the company at strong returns. We think all pathways will have activity that is gonna be attractive. We get the question a lot around redeterminations, and I presume that most of your Medicaid is in the adolescent population, and many of those that would lose traditional Medicaid coverage may just flip into CHIP. It might just be helpful to hear some of the work that you guys have done internally and how you might be thinking about how that plays out over the course of 2023. Thanks. Yeah. Whit, we've been focused on this topic, you know, as it's certainly been out there and now is, I guess, closer to being implemented across the different states than it was as we thought about the potential of it happening over the course of last year. We've had a lot of time to plan. As we've talked about previously, we really view, you know, mental health coverage as essential and think that many states and payers would intend to continue to provide coverage. Of course, we wanna help all of our Medicaid patients navigate, you know, what that means for them, whether it's an administrative process that they go through to re-enroll in their Medicaid plans or find some other product. Our focus has been on educating our patients. Our facilities, our operations leaders, our revenue cycle leaders have done a tremendous job just planning for that and communicating what to expect as we move into the second quarter. We'll continue to monitor the potential impact. Of course, there are patient populations, as you mentioned, the child and adolescent population that I think is less likely to have a disruption and will have a longer period of time where they can stay enrolled in Medicaid. We wanna help all of our patients just navigate what it means for their coverage through the year, and the team's done a nice job preparing. Okay. Thanks, guys. Our next question will come from Kevin Fischbeck with Bank of America. Please go ahead. Okay, great. Thanks. I just wanted to follow up on some of your labor comments, I think last quarter you had talked about kind of 5%-7% wage growth, and it seemed a little bit optimistic that you'd see some moderation in that number over time back to the 3%-4% numbers. I just wanted to get a little more color on kind of why it was so much higher in Q4 when most of the companies seem to be saying that they're seeing some progress on labor. Yeah, Kevin. We did see 5%-7% over the first three quarters of the year. The third quarter was around that 7% level. The fourth quarter, as we isolate just base wage inflation, we were around 8%, which we view as, you know, pretty similar to the 7% that we saw in the third quarter. We do want to remain proactive with our pay, we're seeing an improved environment as we look at just our recruiting metrics, as we look at our net new hires, which improved throughout the fourth quarter and in January and the weekly data that we have for February. We're seeing some positive signs of improvement. We do have, for the company, our annual merit increase process that happens either in January for two-thirds of the company or in April for the other third of the company. We wanna remain committed to that and stay in the right place from a pay perspective across our markets. We have moved forward with that, and partially because of that, expect wage inflation to stay in that 7%-8% range through the first half of this year. With some of those positive metrics that we're seeing with the improvement that we mentioned in premium pay that we saw in the fourth quarter, we're seeing some positive signs. Think as we look out at the second half of the year, we would see wage inflation and our outlook reflects wage inflation, dropping back down below the 5% level. We'll ultimately see if it returns to more of the 3%-4% that the company saw for a number of years and the industry saw for a number of years. For now, second half of the year, we think we would moderate at that point to less than 5% on a base wage inflation. Premium pay, we think, continues to improve throughout the year. Okay. I think last quarter, you kind of broke out some of the labor pressure from things like Center Pointe. Is there anything like that kind of skewing the metrics at all from ramp up of newly opened facilities? I guess, has labor sourcing at all been a headwind to volume growth? Are you having a hard time staffing or is it just you can staff, you just have to pay up for it? Thanks. Appreciate the question on the metrics. We would say, as you look at our labor metrics, including salaries, wages, and benefits as a percentage of revenue, we did have, you know, a $4 million pickup that we recorded and highlighted in the fourth quarter of last year relating to the direct payment program in the state of Florida. That did lower our SWB metric by 30 basis points. Of course, depending on what metric you're looking at here in the fourth quarter of this year, if it's margin, it's impacted by the reserve adjustment that we highlighted. We do have some adjustments that need to be made as you think about the year-over-year metrics. Given that, and within that, we would say our same facility group is performing very well. It's stable year over year and is seeing margin improvement year over year. There are three new facilities that we've opened in the second half of 2022 that do carry a much higher labor load as their volume and revenue ramps. That did have an impact on both the SWB metric as well as our margin. Center Pointe performed well in the fourth quarter. We saw just the team overseeing their integration do a fantastic job throughout the year, bringing improvements to the performance of that acquisition. It did also have an impact on our margin, as, you know, from the acquired date and even in the fourth quarter, that business has a lower margin than the company average. There's a few items like that that did impact our labor metrics. Some investments we've made at the corporate level, which, you know, are having a positive impact on the company as we move into 2023, also are reflected in that SWB and in the margin. Great. Thanks. Our next question will come from Andrew Mok with UBS. Please go ahead. Hi. Good morning. Chris, you mentioned some new investments and facility openings in your prepared remarks, but it wasn't entirely clear to me what changed versus the previous outlook. Can you help us better understand what specifically is driving the higher revenue outlook for 2023 and why that's causing a narrowing of the EBITDA range at this stage? Thanks. Andrew, just to clarify, you're looking for more detail on the IT investments? No, just the 2023 revenue outlook versus the previous outlook you gave at the Investor Day, and why that's causing a narrowing of the EBITDA range at this stage? I mean, Andrew, of course, did provide initial guidance. This is David. We have provided initial guidance in December, earlier than the company typically provides our guidance. We did as we updated that guidance in February, really viewed the now range as a tightening of what we provided in December. I'll say since December, as we've gone through and finalized our, you know, budgeting process, as we've also seen trends through the fourth quarter and the start that we've had to Q1, we did increase our revenue outlook. The key driver of that is that we see our volume accelerating. We talked about the 4% same facility volume growth for the fourth quarter, now accelerating for 2023 to a range of 4%-6%. We are starting Q1 at the high end of that 4%-6% range. We're really pleased with the volume outlook, and it is slightly stronger than what we had projected in December, given some of those strong trends to start the year. The EBITDA outlook, you know, we do believe that that incremental volume drives incremental EBITDA as well. Our view was for now, given it's early in the year, we just tightened our EBITDA range, but kept the midpoint where it was. Of course, you know, things like wage inflation, you know, have also been factored in, just the updated view around that compared to projections that we had in December. Hopefully that helps. Got it. That's helpful. Then on the CapEx, I think it's been about two years in a row now where you've cut the growth CapEx about $85 million lower versus initial expectations. With the step-up in growth CapEx to $375 million this year, what's your confidence level in getting that completed this year? Thanks. Well, it's a good question because as we talked about throughout 2022, we have been looking forward to breaking ground across all of those new facilities that we've had in the pipeline, just ready to start construction and work towards the opening of those new joint ventures and other facilities, and didn't have as much visibility a year ago as we talked about our CapEx guidance as we feel like we have today. There are a number of projects that have now broken ground, and at that point, we do have higher visibility and have a higher confidence level. So we're expecting for that step up to occur, and that's reflected in our guidance. We'll continue to, you know, provide an update as to the timing of those projects. We're glad to be at this moment where we feel like we have higher visibility because the opportunity we have to get those facilities open and bring them into the company, we think is a key driver for our results, you know, two, three years from now. I'm not gonna give you a percentage confidence level, but we do have much higher visibility today, given that we've broken ground across many of those projects. Great. Thanks for all the color. Yeah. Thanks, Andrew. Our next question will come from Gary Taylor with Cowen. Please go ahead. Hi, good morning. I have a question. I noticed in the release, and you had talked about this at Investor Day a little bit about the opportunity to add the Intensive Outpatient Programs at some of your IPFs. The question was, how many of your IPFs have all three or, you know, also include partial hospitalization and the Intensive Outpatient Programs? Is there a way to sort of size the remaining revenue opportunity, either per facility or just for the total company to build out those step-down programs across all the acute hospitals? Thanks, Gary, for the question. This is Chris. I would say a majority of our acute facilities certainly have the opportunity for step-down programs, and that's something, you know, we haven't disclosed the exact number. Clearly that is a focus of our clinical team, led by our Chief Medical Officer, you know, Michael Genovese, as we're trying to continue. We've added obviously, that fifth growth pathway around PHP and IOP, also looking to enhance the cross-referral opportunity within the company as well. David, anything you would wanna add on step-down programs? No, we have seen a number of new programs open over the years, and our team's done a nice job, really looking at, you know, where our patients are coming from, you know, where we might be deflecting patients based on the level of care that's appropriate for them and where they might be stepping down and really using that to open new programs. It also informs our De Novo strategy, just as we think about where we might have service gaps. Happy to bring on a number of new programs at our existing facilities, but it's also really being informed and useful as we think about the De Novo growth and other opportunities where the company might need to add capacity. Could I just do a quick follow? Could you give us a sense of, you have an IPF that doesn't have those two step-down programs, you have an IPF that has kinda mature step-down programs. Is the revenue differential, is it 10% higher, 20% higher? Can you give us any sort of sense on what those step-down programs add to the facility profile? We would probably be ballparking it right now, but I think that 10% range is probably about right. You know, depending on the size of their program, you know, in, in some cases, the facility could have a strong program that's not only step down, it's also capturing other, you know, patients in that market that may just need a different level of care. It does vary by facility, but 10% may be the right estimate. Thank you. Thanks, Gary. Our next question will come from Pito Chickering with Deutsche Bank. Please go ahead. Hi there. You've got Kieran Ryan on here for Pito. Thanks for taking the question. I was just wondering if you could maybe break out the SBC impact in 4Q from the one-time reserve adjustment. I have a quick follow-up after that. As we think about the SWB impact from the reserve adjustment, where that adjustment went on our P&L was actually in other operating expenses, which is where we have our interest expense. Just thinking about it more from a margin perspective and other operating expenses, that metric as a percentage of revenue for the fourth quarter was 13.9%, and without that reserve adjustment would have been 13.0%. That's the impact that it had on that line item and, you know, had about a, you know, 0.9% impact on margin as well. That's helpful. Thank you. Then just on the 2023 EBITDA outlook, could you just break out how much of the change there is due to, like, discretionary investments and facility openings versus just the wage pressure, which seemed to, you know, kind of hold in pretty high there in 4Q in the high single digits? Thank you. Yeah. I mean, our expectation continues to be for those new facilities which do carry some startup losses in the near term, but are an important driver of longer-term value creation and earnings growth for the company. Our, our expectation for 2023 is that those new facilities would still be in the $15 million-$20 million range in terms of where their startup losses should run. That always depends on just the timing of and number of new facilities that we have. That $15 million-$20 million continues to be our estimate for annual startup losses of our new facilities. Thank you. Thank you. Our next question will come from John Ransom with Raymond James. Please go ahead. Good morning. Just a couple on reimbursement. I have one and then a follow-up. If we're looking at apples to apples, just pure rate, 2023 over 2022, how should we think about just the pure rate updates affecting your revenue per day percentage growth? Thanks. Yeah, John, we have a, I'd say compared to December, we have a more positive outlook around reimbursement. Of course, we always go in with expectations for rate increases in the mid-single digit range. It's what we've seen throughout 2022 and, based on inflation and other factors, expect to see that from most of our payers going forward. Wanna remain cautious, just knowing, you know, we have a lot of different payers that we contract with. As we have more recently just thought about what the year looks like from a revenue per day perspective, we are expecting on average 3%-5%. But do feel like in the early part of the year, we have a higher level of visibility that we should sustain growth in the higher end of that range, so closer to that 5%. The reason for that is a lot of our contracting with Medicaid plans, over 75% actually of our Medicaid revenue is contracted in the second half of the year. Which means as we go through the first part of this year, we can see the rate increases that we received over the second half of the year that carry into the first half of this year. The focus is on renegotiating with those payers, you know, in advance of next year's contract date. Do feel like we have higher visibility now. We saw a lot of success across our different facilities, markets, and payers throughout 2022, and hope that that continues in the mid-single digit range and have visibility. We think that it will through the first part of the year. A little more caution just built into the second part of the year where we may see it at the lower end, but we'll obviously stay focused on that. Think we still have opportunities, just building some caution into our outlook for the later part of the year. John, I would just add that, you know, to David's point, you know, we have a very strong corporate managed care team that I think has continued to just build and enhance really good relationships with payers across the board and, you know, has for a number of years. We've chosen to invest in that team and, you know, I think that really factors into, you know, some of the comments that David made. We do wanna be cautious about how all this comes together and just the overall, you know, impact for the company in total. My follow-up is, you know, in theory, as you talk to your commercial and Medicaid partners about value-based kickers, use the baseball analogy kind of where are you? Just in theory, what would that look like for behavioral? Because, you know, we're not used to it being very common in your world. Thanks. To use your baseball analogy, John, I would say we're approaching first base. Very early, very early innings here. you know, we wanna be in a position strategically, and we are doing so with these IT investments, that we're prepared to move at the pace that the industry will move on behavioral health. It's one of the major reasons that we feel so strongly about getting all this infrastructure in place. Making sure that we are able to capture data and that we can ultimately compete on the quality of the clinical outcomes that we're achieving relative to our competitors. I think in terms of value-based programs, it depends on the payer. We certainly are seeing some interest from payers here in the early stages, that, you know, they are willing to provide us with some incentives. Usually it's around readmissions and successfully preventing readmissions. There are, you know, other factors that will probably be added to that over time. These contracts right now that we're seeing are just much more upside-only contracts. We are not seeing any contracts or any interest right now in downside risk or certainly any move to full capitation. That's why I would say we're still approaching first base, and if we, you know, accelerate our pace here to second or third, you know, we'll be ready given the investments that we're making, and that's how we wanna position ourselves to move at that pace. Chris, to be clear, you know, baseball, you're supposed to talk about innings, you know, not bases, but that's okay. I get it. Second inning then, right? Sure. I tried to give you both. That's good. All right. Thanks so much. This concludes our question-and-answer session. I'd like to turn the conference back over to Chris Hunter for closing remarks. Well, thank you. Before we end the call, I just wanna thank again our committed facility leaders, clinicians, and approximately 23,000 dedicated employees across the country who've just continued to work tirelessly to meet the needs of patients in a safe and effective manner. I wanna thank you all for being with us this morning and for your interest in Acadia. If you have any additional questions today, please don't hesitate to contact us directly. Have a great day, everyone. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines.